Johnson & Johnson to Acquire Ollin Biosciences for $2.2 Billion

Johnson & Johnson (JNJ) has entered into an agreement to acquire Texas-based biotechnology firm Ollin Biosciences in a deal valued at up to $3.33 billion. The transaction includes an upfront payment of $2.2 billion, with additional potential milestone payments totaling approximately $1.13 billion contingent on regulatory and commercial achievements. Founded in 2023 and backed by ARCH Venture Partners and Mubadala Capital, Ollin Biosciences focuses on developing therapies for vision-threatening diseases. This acquisition is intended to strengthen Johnson & Johnson's existing pipeline of eye disease treatments. The deal is projected to close by the end of 2026.

By https://www.facebook.com/CNBC · CNBC ·

Johnson & Johnson to Acquire Ollin Biosciences for $2.2 Billion

Tickers: $JNJ

Topics: Acquisition Biotechnology Eye Disease Therapies Healthcare M&A

Read the full article at CNBC

Part of the story Johnson & Johnson in Talks to Acquire Ollin Biosciences for Up to $3.4 Billion (2 articles)

More World news